Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
Moleculin announced that an abstract detailing the cardiac safety profile of its lead drug candidate, Annamycin, has been accepted for a poster presentation at the 2026 ASCO Annual Meeting. The presentation, scheduled for May 30, 2026, will cover a pooled analysis of patients with high cumulative exposure to anthracyclines, highlighting Annamycin's differentiated safety profile.
Key figures
- Drug Name
- Annamycin
- Phase Of Trial
- Phase 3
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.